Carcinoembryonic Antigen in Anal Carcinoma

Tanum, Gunnar; Stenwig, Anna E.; Børmer, Ole P.

doi:10.3109/02841869209108181

Cited by 15 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, three studies failed to meet the inclusion criteria, as the primary form of treatment in these studies was radical surgery rather than chemoradiation. Ultimately, 21 studies remained for full inclusion in this literature review (Figure 1) (Fontana et al , 1991; Tanum et al , 1992; Goldman et al , 1993; Holm and Tanum, 1996; Tanum and Holm, 1996; Allal et al , 1998, 2003, 2004; Grabenbauer et al , 1998; Bonin et al , 1999; Indinnimeo et al , 1999, 2000a, 2000b, 2001; Wong et al , 1999; Holm et al , 2001; Le et al , 2005; Alvarez et al , 2006; Nilsson et al , 2006; Bruland et al , 2008; Ajani et al , 2009). …”

Section: Resultsmentioning

confidence: 99%

“…CEA, a complex glycoprotein that has long been established as a useful adjunct in monitoring patients with colorectal cancer (Goldstein and Mitchell, 2005), was investigated over a decade ago in patients with anal SCC undergoing combined chemoradiotherapy (Table 8) (Tanum et al , 1992). Of the patients, 19% were found to have raised serum CEA levels before treatment and 17.5% of tumours stained positive for CEA, but no correlation with clinical outcome was observed (Tanum et al , 1992).…”

Section: Resultsmentioning

confidence: 99%

“…Of the patients, 19% were found to have raised serum CEA levels before treatment and 17.5% of tumours stained positive for CEA, but no correlation with clinical outcome was observed (Tanum et al , 1992). …”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review

et al. 2010

View full text Add to dashboard Cite

Background:Recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC). However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving >2 years. Further insight into tumour characteristics and molecular biology may identify novel therapeutic targets. This systematic review examines current prognostic markers in SCC of the anus.Methods:An extensive literature search was performed to identify studies reporting on biomarkers in anal cancer in the context of clinical outcome following treatment primarily with chemoradiotherapy.Results:In all, 21 studies were included. A total of 29 biomarkers were studied belonging to 9 different functional classes. Of these biomarkers, 13 were found to have an association with outcome in at least one study. The tumour-suppressor genes p53 and p21 were the only markers shown to be of prognostic value in more than one study.Conclusions:An array of biomarkers have been identified that correlate with survival following chemoradiotherapy in anal cancer. However, investigators are yet to identify a biomarker that has the ability to consistently predict outcome in this disease. Further studies are needed to elucidate whether these candidate biomarkers demonstrate their optimum value when they serve as targets for new therapeutic strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Rectal adenocarcinomas above the reflection were classified as ‘high’ while rectal and anal canal adenocarcinomas below the reflection were classified as ‘low’. Anal canal adenocarcinomas were grouped with rectal cancers owing to a previous study indicating a similar CEA expression profile between these two sites [ 13 ]. For the purpose of this study, ‘recurrent’ cancer refers to local recurrence and distal metastases.…”

Section: Methodsmentioning

confidence: 99%

Differing Serum Cea in Primary and Recurrent Rectal Cancer - A Reflection of Histology?

et al. 2012

View full text Add to dashboard Cite

BackgroundSerum carcinoembryonic antigen (CEA) levels are not universally measured in colorectal cancers. CEA levels have been reported to be usually normal at time of primary rectal cancer diagnosis but elevated in recurrent disease. The aims of the study were to (1) compare serum CEA levels performed at time of primary and recurrent colorectal tumour diagnosis; and (2) to determine serum CEA levels in rectal cancers at primary diagnosis to analyse potential factors influencing differing CEA levels.MethodsA retrospective analysis of patients treated for colorectal cancers at Modbury Hospital, South Australia was performed. Each admission was reviewed within the electronic database. Serum CEA levels and tumour-related factors were determined in patients who underwent curative surgery for their primary tumour and developed tumour recurrence/metastases within the study period.Results438 patients were treated for colorectal cancer in the study period. In patients who underwent curative surgery and developed a recurrence, serum CEA was elevated in 20% patients at primary diagnosis and in 46.6% patients at recurrence. Only 1 of 30 patients with rectal cancer had an elevated CEA at diagnosis of primary tumour. Tumour relationship to the peritoneal reflection did not appear to play a role.ConclusionsIn rectal cancers, serum CEA levels are often normal at the time of initial diagnosis. However, this should not preclude its use in post-operative surveillance. Serum CEA levels noted in primary rectal cancer appear unrelated to the relationship of the tumour to the peritoneal reflection. Stroma-related factors could possibly be involved and merit further investigation.

show abstract

“…Among anal cancer patients, one series examined 106 patients with early-stage SCCA treated definitely with chemoradiation and did not find clinical utility in the measurement of CEA in this subset of patients with anal cancer [ 12 ]. Since no blood-based biomarkers are currently available in a CLIA-certified laboratory for the routine management of SCCA, we performed a retrospective, single-institution study to correlate serum CEA levels with clinical and pathologic outcomes in patients across all stages and presentations of SCCA.…”

Section: Introductionmentioning

confidence: 99%

CEA as a blood-based biomarker in anal cancer

et al. 2021

View full text Add to dashboard Cite

Background: The clinical utility of a blood-based biomarker in squamous cell carcinoma of the anus (SCCA) is unknown. We analyzed carcinoembryonic antigen (CEA), a commonly employed assay for patients with colorectal adenocarcinoma, as a serum biomarker for patients with biopsy-proven SCCA. Materials and Methods: Medical records from 219 patients with biopsy-proven SCCA at the University of Texas MD Anderson Cancer Center were reviewed under an IRB-approved protocol from 2013 to 2020 to assess for correlations between CEA levels and corresponding clinical and pathologic characteristics.Results: The mean CEA among subgroups by clinical status at the time of presentation to our institution was highest among those patients with metastatic SCCA to visceral organs (M-V, 20.7 ng/mL), however this finding was not statistically significant by ANOVA (p = .74). By clinical subgroup, the percentage of patients with an abnormally elevated CEA was highest in those patients with metastatic disease to lymph nodes (M-L, 41.2%) followed by recurrent/unresectable SCCA (36.8%), and metastatic SCCA to visceral organs (M-V, 35.2%), and was statistically significant between groups (Fisher's exact test p = .02). Using RECIST criteria for tumor progression and disease response, the mean change in CEA for patients with progression was an increase in 19 ng/mL, compared to a change of -7.3 ng/mL in those with disease response (p = .004). We likewise assessed whether CEA levels were associated with survival outcomes for all patients with metastatic SCCA, and found no correlation between CEA and likelihood for survival in a ROC analysis (multivariate, age-adjusted analysis for CEA cutoff of 8, HR = 1.01, 95% CI 0.52-1.96).Conclusions: Despite interesting patterns of abnormally high CEA in SCCA patients with advanced disease, and correlation of increased CEA with disease progression (and conversely decreased CEA with disease response), CEA is not associated with survival outcomes in SCCA, and is not a clinically relevant biomarker in this disease.

show abstract

Carcinoembryonic Antigen in Anal Carcinoma

Cited by 15 publications

References 15 publications

Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review

Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review

Differing Serum Cea in Primary and Recurrent Rectal Cancer - A Reflection of Histology?

CEA as a blood-based biomarker in anal cancer

Contact Info

Product

Resources

About